Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Special Issue Letter to the Editor

Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges

Kari Broder, Ahmed Babiker, Charles Myers, Terri White, Heather Jones, John Cardella, Eileen M. Burd, Charles E. Hill, Colleen S. Kraft
Alexander J. McAdam, Editor
Kari Broder
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed Babiker
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Myers
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terri White
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Jones
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Cardella
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eileen M. Burd
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles E. Hill
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen S. Kraft
aDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
bDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander J. McAdam
Boston Children's Hospital
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.01187-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

The SARS-CoV-2 pandemic has changed the face of the globe and upended the daily lives of billions. In an effort to bring mass testing to as many as possible, multiple diagnostic tests, including molecular, antigen detection, and serological assays, have been rapidly developed. Under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), several reverse transcription-PCR (RT-PCR) assays have reached U.S. laboratories, each with its own testing capacity and proprietary methods (1, 2). Multiple logistical challenges have required laboratories to validate and implement multiple platforms for testing, but data on positive percent agreement across platforms are limited. Our institution utilizes the Roche Cobas 6800 SARS-CoV-2 assay, the Cepheid GeneXpert Xpress SARS-CoV-2 assay, and a laboratory-developed test (LDT) based on a modified CDC protocol, but there is no gold standard for the diagnostic accuracy of these assays. Thus, our objective was to determine the degree of agreement between two tests by running the same samples across both platforms and comparing the cycle threshold (CT) values (E target to E target) among samples with high (>30) CT values, corresponding to lower viral loads. We collected 35 positive (positivity determined per assay instructions) nasopharyngeal samples with an E target CT value of ≥30 on the Roche Cobas 6800 assay; those samples then underwent secondary testing on the Cepheid GeneXpert assay within 3 days of initial testing. Discrepancies were resolved using the LDT. All specimens were tested using each manufacturer’s protocol. E target CT values were compared by Bland-Altman analysis. Of 35 samples, 34 tested positive on both instruments. One sample tested positive on the Cobas 6800 assay (CT = 37.9) and negative by the GeneXpert assay and was confirmed to be negative on the LDT. Among the positive samples, CT values were similar between the two assays (P = 0.06). The values ranged from 30.1 to 37.9 (mean, 36.7 ± 1.88) on the Roche Cobas 6800 assay and 24.6 to 42.4 (mean, 32.8 ± 4.07) on the GeneXpert assay. Bland-Altman analysis revealed a bias of 0.33 ± 3.21 (mean difference of −1.59, 95% limits of agreement of −5.97 and 6.63), signifying close agreement between the 2 instruments with a high standard deviation (Fig. 1). Our findings corroborate recently published results which show close agreement between the Cobas 6800 and GeneXpert instruments, in particular, among samples with lower viral loads (3). Our in-house laboratory test determined that the limit of detection (LoD) of the Cobas 6800 assay is 100 copies/ml, and the LoD specified in the GeneXpert package insert is 250 copies/ml. This difference in LoD becomes significant at higher CT values, where the negative bias becomes more pronounced (4, 5). Previous studies have shown that substantial viral loads can be detected around day 5 of infection and drop at differing rates over the course of the illness (6). At our institution, the GeneXpert is utilized as a rapid test (turnaround time, 45 min) to triage patients for admission among other criteria; therefore, it is imperative that our testing modality can capture patients who present at either end of their illness course and who may have lower viral counts/higher CT values. Overall, the Cepheid GeneXpert Xpress SARS-CoV-2 assay and the Roche Cobas 6800 SARS-CoV-2 assay showed a high level of agreement among patients with high CT values. This allows the laboratories to utilize both assays concurrently as fits with local testing algorithms. Further studies are required to confirm percent agreement across different platforms and specimen types to expand on our findings.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Bland Altman plot of agreement. The Bland Altman plot shows CT values with bias of 0.33 ± 3.21 (95% limits of agreement, −5.97 and 6.63).

ACKNOWLEDGMENTS

C.S.K. participated on a Roche advisory board regarding COVID serology. The rest of us have no conflicts.

We acknowledge the staff in the molecular and microbiology laboratories for their assistance in this study.

  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Babiker A,
    2. Myers CW,
    3. Hill CE,
    4. Guarner J
    . 2020. SARS-CoV-2 testing: trials and tribulations. Am J Clin Pathol 153:706–708. doi:10.1093/ajcp/aqaa052.
    OpenUrlCrossRef
  2. 2.↵
    1. Waggoner JJ,
    2. Stittleburg V,
    3. Pond R,
    4. Saklawi Y,
    5. Sahoo MK,
    6. Babiker A,
    7. Hussaini L,
    8. Kraft CS,
    9. Pinsky BA,
    10. Anderson EJ,
    11. Rouphael N
    . 2020. Triplex real-time RT-PCR for severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 26 doi:10.3201/eid2607.201285.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Moran A,
    2. Beavis KG,
    3. Matushek SM,
    4. Ciaglia C,
    5. Francois N,
    6. Tesic V,
    7. Love N
    . 2020. The detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche Cobas SARS-CoV-2 assays. J Clin Microbiol. doi:10.1128/JCM.00772-20.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Giavarina D
    . 2015. Understanding Bland Altman analysis. Biochem Med (Zagreb) 25:141–151. doi:10.11613/BM.2015.015.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Ranganathan P,
    2. Pramesh CS,
    3. Aggarwal R
    . 2016. Common pitfalls in statistical analysis: intention-to-treat versus per-protocol analysis. Perspect Clin Res 7:144–146. doi:10.4103/2229-3485.184823.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Wölfel R,
    2. Corman VM,
    3. Guggemos W,
    4. Seilmaier M,
    5. Zange S,
    6. Müller MA,
    7. Niemeyer D,
    8. Jones TC,
    9. Vollmar P,
    10. Rothe C,
    11. Hoelscher M,
    12. Bleicker T,
    13. Brünink S,
    14. Schneider J,
    15. Ehmann R,
    16. Zwirglmaier K,
    17. Drosten C,
    18. Wendtner C
    . 2020. Virological assessment of hospitalized patients with COVID-2019. Nature. doi:10.1038/s41586-020-2196-x.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges
Kari Broder, Ahmed Babiker, Charles Myers, Terri White, Heather Jones, John Cardella, Eileen M. Burd, Charles E. Hill, Colleen S. Kraft
Journal of Clinical Microbiology Jul 2020, 58 (8) e01187-20; DOI: 10.1128/JCM.01187-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Test Agreement between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges
Kari Broder, Ahmed Babiker, Charles Myers, Terri White, Heather Jones, John Cardella, Eileen M. Burd, Charles E. Hill, Colleen S. Kraft
Journal of Clinical Microbiology Jul 2020, 58 (8) e01187-20; DOI: 10.1128/JCM.01187-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

COVID-19
RT-PCR
SARS-CoV-2
diagnostics
virology

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X